Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in other brain neurons (1 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 167 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 15211
Sealed predictions
- BTNL2 in dopamine neurons, braak+0.00 (p 1.000) → +0.19 (p 0.631)receipt 15218
Swarm cases
receipt 15218: BTNL2 in dopamine neurons, braak
- power
- full sample +0.08 (p 0.754, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.07 (p 0.774, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.04 (p 0.867, n 18). could be the mix.
- skeptic
- leave-one-out range -0.06 to +0.18, sign flips 3; without severely affected donors +0.08 (p 0.754, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for BTNL2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts